HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.

@article{Spraggs2011HLADQA10201IA,
  title={HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.},
  author={Colin F Spraggs and Laura R Budde and Linda P Briley and Nan X Bing and Charles J. Cox and Karen King and John C. Whittaker and Vincent E. Mooser and Alaknanda J Preston and Steven H Stein and Lon R. Cardon},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 6},
  pages={667-73}
}
PURPOSE Hepatobiliary adverse events (AEs) have been observed in a small proportion of patients with metastatic breast cancer (MBC) treated with lapatinib. This study sought to identify gene variants associated with lapatinib-induced ALT elevation and hepatobiliary AEs. PATIENTS AND METHODS A two-stage pharmacogenetic investigation of ALT elevation was conducted in lapatinib-treated patients with MBC. Exploratory marker identification evaluated classical HLA alleles, candidate genes, and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Tykerb package insert

  • MP Manns, EF Johnson, KJ Griffin
  • 2010

Lapa - tinib combined with letrozole versus letrozole and placebo as first - line therapy for postmenopausal hormone receptor - positive metastatic breast can

  • B Moy, PE Goss
  • J Clin Oncol
  • 2009

Similar Papers

Loading similar papers…